vt-1161 and Mucormycosis

vt-1161 has been researched along with Mucormycosis* in 2 studies

Other Studies

2 other study(ies) available for vt-1161 and Mucormycosis

ArticleYear
Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9

    We compared prophylactic or continuous therapy with the investigational drug VT-1161 to that with posaconazole in treating murine mucormycosis due to

    Topics: Animals; Antifungal Agents; Immunocompromised Host; Male; Mice; Microbial Sensitivity Tests; Mucormycosis; Protective Agents; Pyridines; Rhizopus; Tetrazoles; Triazoles

2017
VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

    Topics: Amphotericin B; Animals; Antifungal Agents; Immunocompromised Host; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mucormycosis; Pyridines; Rhizopus; Species Specificity; Survival Analysis; Tetrazoles

2015